Olatorepatide: how a domestic pharma “built on oncology” turned weight loss into a US$2 billion going-global case study

First, Hansoh itself. In fiscal 2025 the company had revenue of about RMB 15.028 billion (up 22.6% year on year) and profit for the year of about RMB 5.555 billion (up 27.1%), with innovative and collaboration product revenue of about RMB 12.354 billion, already 82.2% of the total, and R&D expenditure of about RMB 3.358 billion (up 24.3%). This is a domestic giant that has thoroughly completed the “generic-to-innovative transformation”.

But the revenue structure reveals its center of gravity: the oncology segment contributed about RMB 9.974 billion, 66.4% of total revenue, while metabolic products contributed about RMB 2.158 billion, 14.3%. In other words, Hansoh is a company “built on oncology, with metabolism as a supplement”. This is crucial — it means the weight-loss asset will always have to compete internally for resources and management attention with oncology cash cows like aumolertinib.

So why still bet heavily on weight loss? Because Hansoh is no newcomer to metabolism. It already has an in-house once-weekly GLP-1 receptor agonist — Fulaimei (polyethylene glycol loxenatide) — for type 2 diabetes, with a supporting endocrinology commercial team, hospital network and KOL resources already in place. Olatorepatide is not starting from zero but standing on a platform that has already run GLP-1 commercialization successfully. This is its most underrated trump card.

In March 2026, Hansoh released results from the China Phase 3 registration study HS-20094-301, the backbone of olatorepatide’s value narrative:

How to read these numbers? Weight loss of 19.3% at 48 weeks already falls near the range of tirzepatide’s SURMOUNT studies. But stay calm: tirzepatide’s signature data were read out at 72 weeks, a longer time point with a higher weight-loss plateau; the two cannot simply be equated, and cross-trial comparison is always a rose with thorns.

The differentiation story olatorepatide really wants to tell is not the magnitude of weight loss itself, but gastrointestinal tolerability. Nausea below 10% and vomiting below 5% are clearly milder than publicly available Phase 3 data for peer dual agonists. In a race where weight-loss magnitude is gradually “competing up to the ceiling”, tolerability, discontinuation rates and adherence are becoming new dimensions of competition. This is a clever positioning — but it has a fatal precondition: the lack of a head-to-head study against tirzepatide. Without head-to-head, “better tolerability” remains at the level of a cross-trial narrative and is hard to turn into hard currency at the prescribing end.

There are also data supporting the diabetes direction. In the Phase 2 proof of concept disclosed at ADA 2024, olatorepatide showed dose-dependent reductions in HbA1c within 4 weeks, numerically no worse than the semaglutide comparator arm. This leaves room for imagination for the larger diabetes indication later and supports its positioning as a “metabolic platform asset” rather than a “single weight-loss product”.

From a registration standpoint, olatorepatide’s China path is quite clean: an independent Chinese Phase 3 registration study has met its co-primary endpoints, the data package is solid, and NDA submission is imminent. The trial started in November 2024 and completed its primary analysis in early 2026, with well-controlled pace. The standard review channel and a label for long-term weight management in adults hold no suspense.

But a “clear path” does not mean a “leading position”. Stretching out the timeline shows that olatorepatide is not among the first batch of players in China:

Hengrui’s and Innovent’s dual/multi-agonist NDAs both came before olatorepatide, and tirzepatide has already launched and cut its price to 20% of the original. This means that when olatorepatide enters the Chinese market it will no longer enjoy the window dividend of a “first-in-mechanism” launch; it will have to win share through tolerability differentiation and Hansoh’s own commercial platform, not through being first in line.

This is the most intriguing part of the asset. Hansoh made a clear “cut” for olatorepatide: it kept Greater China (mainland, Hong Kong, Macau) and exclusively licensed all other regions worldwide to Regeneron.

First, where the deal is clever. For a domestic pharma with almost no overseas clinical and commercial capabilities, handing global development rights to an MNC with a cardiometabolic heritage that is eager to enter the GLP-1 race is a reasonable choice to leverage global value with minimal own investment. Regeneron holds a big lipid-lowering product like Praluent, and co-formulating olatorepatide with it targets a “weight loss + lipid lowering” cardiometabolic combination story — a synergy Hansoh itself could never tell. With US$80 million in hand and nearly US$2 billion in milestones on the books, closed at the hottest point of the 2024–2025 GLP-1 M&A window, the timing was also spot on.

But the structural risk of this deal is hidden precisely in the act of “splitting”.

First, this is not a true “regional sublicensing” but “betting all overseas territory on a single partner”. A typical regional split (for example, licensing the US, Europe and Japan separately to different partners) spreads risk; Hansoh instead handed all rights outside Greater China to Regeneron alone in one go. This means all overseas value hangs on the execution and weight-loss strategic resolve of one company, Regeneron. Regeneron is an out-and-out newcomer to GLP-1, and its ability to scale commercially has not been proven; if its weight-loss priorities change, olatorepatide’s overseas story will cool accordingly, and Hansoh has almost no means of hedging.

Second, value is “light up front, heavy at the back”. The US$80 million upfront is only about 4% of total deal value. The vast majority of value is locked in milestones and royalties, dependent on Regeneron subsequently running global Phase 3 successfully and selling the product. In other words, Hansoh got a cheque that “looks big”, but the pace of realization is entirely out of its hands.

Third, dual-track development plants the risk of label divergence. With China advanced by Hansoh and overseas led by Regeneron, the two tracks run independently and are likely in future to diverge on dose, indications and brand name. When a global brand presents differently in different markets, cross-market academic narrative and brand momentum are both weakened.

So the question comes back to where it started: since overseas has been handed over, Greater China becomes the only value anchor Hansoh can fully control. And this anchor lands precisely where it is strongest — its own commercial platform.

This is the supporting logic: Hansoh has the endocrinology network, hospital access pathways and medical influence in metabolism accumulated through Fulaimei, and olatorepatide can plug “seamlessly” into this system, forming sequential synergy from diabetes to weight loss with the existing GLP-1 product. In the Chinese market, it is not taking the hard road of “building a team from zero for a new molecule”, but the shortcut of “a mature platform amplifying a single product”. This is the fundamental reason it still has a fighting chance in China’s crowded weight-loss market.

Competition among weight-loss drugs is ultimately often decided not on clinical endpoints but on capacity and cost. As a long-chain peptide with a fatty acid side-chain modification, olatorepatide’s solid-phase synthesis cost rises significantly with chain length; meanwhile China’s weight-loss market is going through a brutal price war, with tirzepatide already at 20% of its original price. High synthesis cost × low end-market price squeezes gross margin from both sides — the common Achilles’ heel of all domestic peptide weight-loss drugs.

Supply continuity is another pressure. Against the backdrop of semaglutide and tirzepatide scaling globally and competing for peptide CDMO capacity, API supply is not easy for any latecomer. Although Hansoh has accumulated a quality system through exports and multiple out-licensing deals, commercial-scale peptide process scale-up, passing global GMP inspections, and the additional CMC complexity of a co-formulation with Regeneron are all links that still need time to prove.

On the positive side, this asset has a lot of room in dosage forms and lifecycle — oral formulation, different strengths, injection device upgrades, co-formulation with lipid-lowering drugs; each direction is a potential means of differentiation and life extension.

Back to the tension at the start of this article. Within Hansoh’s metabolic segment, olatorepatide is without doubt the number-one asset and the going-global flagship. Senior management endorsed it with a US$2 billion-class deal, and the R&D budget (RMB 3.358 billion company-wide) is not a constraint.

But across the company as a whole, it ranks behind the oncology pipeline. When two-thirds of revenue and profit come from oncology, and products like aumolertinib are still scaling and still being out-licensed (two B7-H3/B7-H4 ADC deals with GSK and aumolertinib’s own overseas license are all under way), metabolic assets naturally sit in the “second-tier priority” position in the competition for R&D resources, commercial investment and management attention. This is not a flaw but a reality that should be seen honestly: olatorepatide’s resource supply will always have to give way to the company’s oncology base.

On the positive side, Hansoh has built a deep “oral (HS-10535 licensed to MSD) + injectable (HS-20094 licensed to Regeneron, Greater China self-commercialized)” layout in metabolism, with multiple routes and multiple partners in parallel. But this layout has a cost too — different routes belong to different partners, and the synergy a platform should have is cut into pieces; Hansoh looks more like an “incubation and licensing platform for metabolic assets” than a unified operating weight-loss player.

Olatorepatide is a carefully designed asset: positioned clinically on tolerability, with a clean registration path, a deal that caught the hot going-global window, and a mature platform as a commercial backstop. It has done almost everything a domestic pharma company can do right in the weight-loss race.

But its fate will ultimately be decided by two variables it cannot fully control — overseas, a bet on the execution of one company, Regeneron; in China, a bet on a market being reshaped by a price war. Hansoh sold overseas rights at a good price and kept China on its strongest suit — a pragmatic and restrained good move. The real test is whether, as the global weight-loss war enters its second half of triple agonists and oral molecules, this “precisely timed fast follower” can collect all the value it is due before being overtaken.

For a company built on oncology, olatorepatide perhaps doesn’t need to become the next king of weight loss. It is enough for it to become “a going-global case study whose numbers add up”.